8-K

                                  UNITED STATES
                        SECURITIES AND EXCHANGE COMMISSION
                              Washington, D.C. 20549
                                   ____________

                                     FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported)
                         April 13, 2009 (April 13, 2009)
                                   ____________

                         DIALYSIS CORPORATION OF AMERICA
             (Exact name of registrant as specified in its charter)

           Florida                       0-8527                59-1757642
(State or other jurisdiction           (Commission           (IRS Employer
       of incorporation)               File Number)       Identification No.)

1302 Concourse Drive, Suite 204, Linthicum, MD                   21090
   (Address of principal executive offices)                   (Zip Code)

     Registrant's telephone number, including area code: (410) 694-0500

                                   ____________

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

[  ] Written communications pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))



Item  8.01. Other Events

     Effective as of April 13, 2009, the Board of Directors of Dialysis
Corporation of America (the "Company") approved a stock repurchase program,
pursuant to which the Company may purchase up to $3 million of its issued and
outstanding shares of common stock.  On April 13, 2009 the Company issued a
press release announcing its stock repurchase program. A copy of the press
release is furnished as Exhibit 99.1 to this Report.

Item  9.01.  Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated April 13, 2009

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereto duly authorized.

                             DIALYSIS CORPORATION OF AMERICA

                                /s/ Stephen W. Everett
                             By-----------------------------------
                                STEPHEN W. EVERETT
                                President and Chief Executive Officer

Dated:  April 13, 2009



                                   EXHIBIT INDEX

Exhibit No.
- -----------

    99.1 Press Release dated April 13, 2009

EX-99

                                 Press Release

                       Dialysis Corporation of America
                                   Announces
                           Share Repurchase Program

Linthicum, Maryland, April 13, 2009 - Dialysis Corporation of America
(NASDAQ-DCAI) announced that its Board of Directors has approved a stock
repurchase program, effective April 13, 2009. Under the program, the company
is authorized to repurchase up to $3 million of its outstanding shares of
common stock from time to time, depending on market conditions, share price
and other factors.

The stock purchases will be made out of available cash in open market
transactions at the prevailing market price or through privately negotiated
transactions.

"This stock repurchase program underscores the level of confidence we have in
our company and is aligned with our commitment to deliver long-term
shareholder value," said Thomas K. Langbein, Chairman of the Board.

The duration of the repurchase program is open-ended but may be suspended or
discontinued at any time in the discretion of the company's management
without prior notice. As of April 13, 2009, the company had approximately 9.6
million shares of common stock outstanding.

Dialysis Corporation of America owns and operates freestanding kidney
hemodialysis centers located in Georgia, Maryland, New Jersey, Ohio,
Pennsylvania, South Carolina, and Virginia, and provides in-hospital dialysis
services on a contract basis to certain hospitals located in the those
states.  The company provides patients with their choice of a full range of
quality in-center, acute or at-home hemodialysis services.

This release contains forward-looking statements that are subject to risks
and uncertainties that could affect the business and prospects of the company
and cause actual results and plans to differ materially from those
anticipated. Those factors include, but are not limited to, increases in
interest rates, the possible need for and availability of additional
financing, the company's satisfying the covenants and conditions of its
credit facility, certain delays beyond the company's control with respect to
future business events, the highly competitive environment in the
establishment and operation of dialysis centers, the ability to develop or
acquire additional dialysis facilities, whether patient bases of the
company's dialysis facilities can mature to provide profitability, the
extensive regulation of dialysis operations, government rate determination
for Medicare reimbursement, pricing pressure from private payors, and other
risks detailed in the company's filings with the SEC, particularly as
described in the company's annual report on Form 10-K for the fiscal year
ended December 31, 2008. The historical results contained in this press
release are not necessarily indicative of future performance of the company.

Other Dialysis Corporation of America press releases, corporate profile,
corporate governance materials, quarterly and current reports, and other
filings with the Securities and Exchange Commission are available on Dialysis
Corporation of America's internet home page:
http://www.dialysiscorporation.com.

CONTACT: For additional information, you may contact Dialysis Corporation of
America, 1302 Concourse Drive, Suite 204, Linthicum, MD 21090; Telephone
Number (410) 694-0500; Attention: Investor Relations.

Source: Dialysis Corporation of America